autologous BAFF-expressing CAR T cells LMY-920

A preparation of autologous cluster of differentiation 4 (CD4) -and CD8 positive T lymphocytes that are genetically engineered, using the non-viral transposon system, to express a chimeric antigen receptor (CAR) expressing the B-cell activating factor (BAFF) ligand and targeting BAFF receptor family members, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous BAFF-expressing CAR T cells LMY-920 are directed to, specifically bind to, and induce selective toxicity in tumor cells expressing any of the three BAFF receptor family members, including BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA), and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Almost all B-cell cancers are reported to express at least one of these three receptors which play a key role in the regulation of peripheral B-cell survival.